AbbVie (NYSE: ABBV) reported Q4 EPS of $3.60, $0.07 better than the analyst estimate of $3.53. Revenue for the quarter came in at $15.12 billion versus the consensus estimate of $15.33 billion.

• These Results Include an Unfavorable Impact of $0.13 Per Share Related to Fourth-Quarter 2022 Acquired IPR&D and Milestones Expense

GUIDANCE:

AbbVie sees FY2023 EPS of $10.70-$11.10, versus the consensus of $11.65.

For earnings history and earnings-related data on AbbVie (ABBV) click here.